Published on
June 7, 2022

Mindset Pharma to Participate in Upcoming Conferences in June 2022

TORONTO, June 07, 2022 (GLOBE NEWSWIRE) -- Mindset Pharma Inc. (CSE: MSET) (FSE: 9DF) (OTCQB: MSSTF) ("Mindset" or the "Company"), a drug discovery and development company focused on creating optimized and patentable next-generation psychedelic medicines to treat neurological and psychiatric disorders with unmet medical needs, today announced that management will participate in three upcoming conferences:

  • Grizzle Psychedelics Con 2022 to be held virtually on Wednesday, June 8, 2022. James Lanthier, CEO of Mindset will present at 10:15 a.m. ET. To attend, join here.

  • Charles River’s Re-Imagining Substance Abuse, Addiction, and Mental Health Disorders with Psychedelic Therapies Symposium to be held at the AC Hotel in San Francisco, CA on Thursday, June 9, 2022. Fiona Randall, SVP, External Alliances and Scientific Strategy of Mindset, will participate in the Commercializing Psychedelics from Hoffman’s Bicycle Ride to the Electric Car panel at 1:35 p.m. PT. In addition, Dr. Randall will present Developing Novel Psychedelic-Inspired Medicines at 3:30 p.m. PT. To attend, register here.

  • H.C. Wainwright 1st Annual Mental Health Conference: Neuropsychiatry, Psychedelics, and Beyond to be held at the Lotte New York Palace Hotel in New York City on June 27, 2022. To attend, register here.

For more information about the conferences, or to schedule a one-on-one meeting with Mindset management, please contact your appropriate representative directly, or send an email to KCSA Strategic Communications at

About Mindset Pharma Inc.
Mindset Pharma Inc. is a drug discovery and development company focused on creating optimized and patentable next-generation psychedelic medicines to treat neurological and psychiatric disorders with unmet needs. Mindset was established in order to develop next-generation pharmaceutical assets that leverage the breakthrough therapeutic potential of psychedelic drugs. Mindset is developing several novel families of next-generation psychedelic compounds, as well as an innovative process to chemically synthesize psilocybin in addition to its own proprietary compounds. The company has a co-development agreement with the McQuade Center for Strategic Research and Development, a member of the Otsuka Pharmaceuticals family of companies, for its short-duration compounds, Mindset Families 2 & 4.

For further information on Mindset, please visit our website at

For more information, please contact:

Investor Contact:
Allison Soss
KCSA Strategic Communications
Phone: 212-896-1267
Media Contact:
McKenna Miller
KCSA Strategic Communications
Phone: 949-606-6585

Company Contact:
James Lanthier, CEO

Jason Atkinson, VP, Corporate Development
Phone: 416-479-4094

Forward-Looking Information
This news release contains certain "forward-looking information" within the meaning of applicable securities law. Forward looking information is frequently characterized by words such as "plan", "expect", "project", "intend", "believe", "anticipate", "estimate", "may", "will", "would", "potential", "proposed" and other similar words, or statements that certain events or conditions "may" or "will" occur. These statements are only predictions. Forward-looking information is based on the opinions and estimates of management at the date the information is provided and is subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those projected in the forward-looking information. Additional information regarding risks and uncertainties relating to the Company's business are contained under the heading "Risk Factors" in the Company's annual information form for the financial year ended June 30, 2020 dated March 5, 2021. The forward-looking information included in this news release is made as of the date of this news release and the Company does not undertake an obligation to publicly update such forward-looking information to reflect new information, subsequent events or otherwise, except as required by applicable law.